COVID-19 Vaccines Are Coming Soon, But Therapeutics Needed Now
Executive Summary
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.
You may also be interested in...
Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic
Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate.
Regeneron Pressed About Pending COVID-19 Antibody EUA
CEO Len Schleifer said he does not know the timeline for when the US FDA could authorize REGN-COV2 but expects to hear from the agency soon.
COVID-19 Vaccine Should Demonstrate At Least 50% Effectiveness, US FDA Says
Guidance on COVID-19 vaccine development and licensure appears to set a precedent in specifying the clinical efficacy rate for a product approval; agency also takes accelerated approval off the table for now and says emergency use authorization may be granted only after safety and efficacy have been demonstrated.